loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Ixabepilone

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Ixabepilone

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PRICE INFORMATION

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    DIGITAL CONTENT

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 1,494,337Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Data from Allarity's PII Trial of IXEMPRA Indicate Potential for Benefit in DRP
    Data from Allarity's PII Trial of IXEMPRA Indicate Potential for Benefit in DRP

    05 Jul 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/07/05/2699631/0/en/Initial-Data-from-Allarity-s-Phase-2-Trial-of-IXEMPRA-Indicate-Potential-for-Improved-Clinical-Benefit-in-DRP-Selected-Metastatic-Breast-Cancer-Patients.html

    GLOBENEWSWIRE
    05 Jul 2023
    Share Share
    Oncology Venture advancing towards next milestone clinical Dev of IXEMPRA®.
    Oncology Venture advancing towards next milestone clinical Dev of IXEMPRA®.

    13 Nov 2019

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2019/11/13/1946075/0/en/Oncology-Venture-advancing-towards-next-milestone-in-its-clinical-development-of-IXEMPRA.html

    GLOBENEWSWIRE
    13 Nov 2019
    Share Share
    Copycats wanted: Pfizer, AZ and more under threat as China solicits generics
    Copycats wanted: Pfizer, AZ and more under threat as China solicits generics

    21 Jun 2019

    // Angus Liu FIERCE PHARMA

    https://www.fiercepharma.com/pharma-asia/foreign-drugmakers-under-threat-as-china-rolls-out-drug-list-to-boost-generic

    Angus Liu FIERCE PHARMA
    21 Jun 2019
    Share Share